npj Precision Oncology

Article	Citations
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	140
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	96
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	71
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	66
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	64
Microbiome dysbiosis in lung cancer: from composition to therapy	64
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	61
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	61
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	60
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	56
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	50
GD2 CAR T cells against human glioblastoma	50
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	47
Will polygenic risk scores for cancer ever be clinically useful?	43
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors	42
Survival improvement for patients with metastatic colorectal cancer over twenty years	40
Clinical application of a lung cancer organoid (tumoroid) culture system	40
Antibody-drug conjugates in lung cancer: dawn of a new era?	40
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	38
Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology	38
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer	37
Identification of gastric cancer subtypes based on pathway clustering	36
Deep learning for end-to-end kidney cancer diagnosis on multi-phase abdominal computed tomography	35
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	34
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance	34

Targeting CDK1 in cancer: mechanisms and implications	33
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors	33
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	33
Dynamic roles of inflammasomes in inflammatory tumor microenvironment	33
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	33
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients	32
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer	32
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance	31
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer	30
Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images	29
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma	29
Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology	29
Just Add Data: automated predictive modeling for knowledge discovery and feature selection	29
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer	29
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas	28
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC	27
Cell graph neural networks enable the precise prediction of patient survival in gastric cancer	27
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy	27
Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies	27
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA	26
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes	26
Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review	26
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy	25
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient	25
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome	24
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma	24
Prostate cancer polygenic risk score and prediction of lethal prostate cancer	24
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma	24
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients	24
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury	23
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	23
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients	23
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade	22
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer	22
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets	21
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features	20
A deep learning model for molecular label transfer that enables cancer cell identification from histopathology images	20
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells	20
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition	20
Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials	20
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer	20
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors	19
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer	19
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics	19
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade	19
Deep learning generates synthetic cancer histology for explainability and education	19
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma	19
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns	19
Spatially variant immune infiltration scoring in human cancer tissues	19
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis	19

Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor	19
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	19
Genomic landscape of 891 RET fusions detected across diverse solid tumor types	18
Artificial intelligence in ovarian cancer histopathology: a systematic review	18
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?	18
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	18
Imaging immunity in patients with cancer using positron emission tomography	18
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial	18
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations	17
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	17
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance	17
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors	17
Precision medicine: affording the successes of science	17
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma	17
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups	17
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types	17
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer	16
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations	16
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions	16
Rare deleterious germline variants and risk of lung cancer	16
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia	16
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	16
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features	16
Artificial intelligence for the next generation of precision oncology	16
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia	16
Impact of TP53 mutations in Triple Negative Breast Cancer	15
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1	15
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target	15
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma	15
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer	15
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial	15
MatchMiner: an open-source platform for cancer precision medicine	15
Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case	15
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM	15
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer	15
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis	15
Racial and ethnic disparities in a real-world precision oncology data registry	15
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer	15
Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes	14
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification	14
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies	14
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology	14
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia	14
First-in-human prospective trial of sonobiopsy in high-grade glioma patients using neuronavigation-guided focused ultrasound	14
Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment	14
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy	13
Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study	13
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer	13
ALK fusions in the pan-cancer setting: another tumor-agnostic target?	13
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer	13
Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors	13
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer	13
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study	13
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations	13
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing	13
Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium	13
Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma	13
Tumor-associated macrophage-related strategies for glioma immunotherapy	13
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration	13
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients	13
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression	13
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma	12
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition	12
Prediction of early-stage melanoma recurrence using clinical and histopathologic features	12
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer	12
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy	12
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics	12
Advances in NK cell therapy for brain tumors	12
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality	12
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer	12
Patient-level proteomic network prediction by explainable artificial intelligence	12
Radiomics for characterization of the glioma immune microenvironment	12
Epigenomics and immunotherapeutic advances in pediatric brain tumors	12
Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma	12
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity	12
A DNA methylation-based liquid biopsy for triple-negative breast cancer	12
DNA-based copy number analysis confirms genomic evolution of PDX models	12
Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy	11
Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients	11
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)	11

Preoperative immune landscape predisposes adverse outcomes in hepatocellular carcinoma patients with liver transplantation	11
Integrated molecular and clinical analysis of BRAF-mutant glioma in adults	11
Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology	11
Comprehensive RNA analysis of CSF reveals a role for CEACAM6 in lung cancer leptomeningeal metastases	11
BAP1 methylation: a prognostic marker of uveal melanoma metastasis	11
Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis	11
Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction	11
Multi-site desmoplastic small round cell tumors are genetically related and immune-cold	11
Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients	11
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells	10
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer	10
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework	10
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression	10
Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma	10
A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival	10
Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review	10
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma	10
Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements	10
A patient-designed tissue-engineered model of the infiltrative glioblastoma microenvironment	10
Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts	10
Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinoma	10
FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation	9
Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication	9
STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis	9
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib	9
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers	9
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system	9
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity	9
The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer	9
Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy	9
HER3 targeting augments the efficacy of panobinostat in claudin-low triple-negative breast cancer cells	8
Clinical prospects of WRN inhibition as a treatment for MSI tumours	8
All models are wrong and yours are useless: making clinical prediction models impactful for patients	8
An appraisal of genetic testing for prostate cancer susceptibility	8
ESCCAL-1 promotes cell-cycle progression by interacting with and stabilizing galectin-1 in esophageal squamous cell carcinoma	8
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition	8
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing	8
ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression	8
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies	8
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study	8
Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAFV600E-driven human cancers	8
Rewiring of the N-Glycome with prostate cancer progression and therapy resistance	8
Panels and models for accurate prediction of tumor mutation burden in tumor samples	8
Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment	8
A single-cell based precision medicine approach using glioblastoma patient-specific models	8
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas	8
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas	8
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	8
Peripheral blood DNA methylation profiles predict future development of B-cell Non-Hodgkin Lymphoma	8
Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer	8
Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma	8
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway	7
Are sex and gender considered in head and neck cancer clinical studies?	7
Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature	7
GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer	7
Locoregional tumor burden and risk of mortality in metastatic breast cancer	7
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling	7
An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading	7
Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies	7
PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN	7
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology	7
Determinants of response to CDK4/6 inhibitors in the real-world setting	7
Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers	7
Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma	7
Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma	7
Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy	7
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer	7
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade	7
MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NFκB pathways accelerates G1/S transition promoting breast cancer progression	7
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors	7
The regulatory role of cancer stem cell marker gene CXCR4 in the growth and metastasis of gastric cancer	7
Large language models and multimodal foundation models for precision oncology	7
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	7
Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations	6
Single-cell and spatial analyses revealed the co-location of cancer stem cells and SPP1+ macrophage in hypoxic region that determines the poor prognosis in hepatocellular carcinoma	6
Polygenic risk scores to stratify cancer screening should predict mortality not incidence	6
Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy	6
Ribosome biosynthesis and Hedgehog activity are cooperative actionable signaling mechanisms in breast cancer following radiotherapy	6
Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling	6
Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers	6
Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy	6
Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment	6
The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer	6
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells	6
Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance	6
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients	6
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology	6
High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival	6
Multi-omics analysis reveals NNMT as a master metabolic regulator of metastasis in esophageal squamous cell carcinoma	6
Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer	5
HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients	5
Scientific figures interpreted by ChatGPT: strengths in plot recognition and limits in color perception	5
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	5
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy	5
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC	5